P2.07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab

W. Park,D. Kwon,D. Saravia,A. Desai, J. Warsch,F. Vargas,M. El Dinali,R. Elias,Y. Chae, D.W. Kim,S. Warsch,A. Ishkanian,C. Ikpeazu,R. Mudad,G. Lopes,M. Jahanzeb

JOURNAL OF THORACIC ONCOLOGY（2017）

引用 0|浏览27

暂无评分

摘要

Despite significant improvement of clinical outcomes of the patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors, our knowledge of optimal predictive and prognostic biomarkers are still evolving.

查看译文

关键词

biomarker,Advanced Non-Small Cell Lung Cancer,Nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要